Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
about
A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic micePhase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaMechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.Initial testing of lenalidomide by the pediatric preclinical testing programAntiaging effect of pine pollen in human diploid fibroblasts and in a mouse model induced by D-galactoseReduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).The biology of uveal melanomaSynergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.Hyperosmolarity-mediated mitochondrial dysfunction requires Transglutaminase-2 in human Corneal epithelial cells
P2860
Q28542823-E7CEFB29-42E8-4B73-94EA-E2B6727504FFQ33408279-C0EFB754-4326-45E0-98FD-12EB0EDF5FE7Q33728406-2552FD23-84ED-49DA-AFCE-AEC1EC223FB7Q33838091-6BA2A5C7-F576-4C64-A8E5-0B65D05849E2Q33960866-6FBA9C22-FDC6-4981-95ED-67B7DC2EE702Q35033514-B9FA5C58-B838-4C69-9941-5A18F3F53934Q35033519-D8C022E9-CE5B-4ACA-9E2C-FDA2BB0E8747Q35171777-F90991F0-0F2F-48FD-8B49-F3633B494DE9Q35232168-BC4182D6-A075-418C-A549-5C2A6B82B849Q35861457-FB358FA9-7C3D-4A39-A3C3-7519920478FAQ35936749-95177943-D4FF-41B3-A8D5-D9E84B6CE0EFQ36003724-1F6A77E9-F113-4ACD-B8A9-49E078D01C67Q37330741-3C802813-0850-444E-B0FC-D29B0FF2C0DEQ37742632-E7C35703-7723-400C-8F7C-11E0428853E6Q39078319-8BB0EC3E-5584-4F75-B6DB-991FD22D2E64Q56775815-B1E1FD81-7143-4C58-8E9A-C15C6CD4A7EF
P2860
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combination therapy targeting ...... model of human ocular melanoma
@ast
Combination therapy targeting ...... model of human ocular melanoma
@en
type
label
Combination therapy targeting ...... model of human ocular melanoma
@ast
Combination therapy targeting ...... model of human ocular melanoma
@en
prefLabel
Combination therapy targeting ...... model of human ocular melanoma
@ast
Combination therapy targeting ...... model of human ocular melanoma
@en
P2093
P2860
P356
P1476
Combination therapy targeting ...... model of human ocular melanoma
@en
P2093
David I Stirling
David P Mangiameli
Dominique Lorang
George W Muller
Joseph A Blansfield
Peter H Schafer
Stephan Kachala
Steven K Libutti
P2860
P2888
P356
10.1186/1479-5876-5-38
P577
2007-07-18T00:00:00Z
P5875
P6179
1014935821